Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Almost 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 2,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.
As a trusted tool provider for clinicians and industry, from large to small, CliniMACS® Systems provide technologies and instruments to the clinic. From immuno-oncology, regenerative medicine, to graft engineering, you’ll find comprehensive solutions for numerous clinical settings.
Using CliniMACS Systems, cell products have been manufactured for all stages of clinical development - from discovery to IND submission and ongoing clinical trials. We are committed to supporting investigators with solutions that enable the clinical translation and practice of novel cell and gene therapies. This support includes products and services that extend the value beyond the device and consumables.
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. Together with our customers, we unlock the potential of blood and cellular therapies to enable better lives
BIA Separations specializes in chromatographic purification of the most challenging biomolecules. The ability of a purification process to deal with big vulnerable molecules and stubborn impurities, for example, hcDNA, is a distinctive advantage. BIA’s downstream platforms are based on unique monolithic chromatographic media, namely, CIM® monolithic columns, distinguished for their flow independent performance, resulting in fast separation, concentration, purification and analytics. Elaborate column design reduces shear stress that vulnerable molecules are subjected to, thus significantly increases final recovery. Cutting-edge applications focus on downstream processing of exosomes, viruses (AAV, Influenza, etc.), plasmid DNA, bacteriophages and mRNA. We provide products that range from small analytical columns to large industrial prep-scale columns (including cGMP and disposable units in IEX, HIC, affinity and customized formats). As such, our products are used in research, laboratory, pilot and industrial production stages and are extremely simple to use, with no packing of columns needed.
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With over 180 experts focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit https://ct.catapult.org.uk.
Sartorius Stedim Biotech is a leading international provider of integrated solutions for the biopharmaceutical industry. With our extensive portfolio of products, technologies and services, we cover wide areas of the biopharmaceutical process chain, ranging from fermentation, cell cultivation, filtration and purification to media storage and transportation. In process filtration, fermentation and fluid management, our company holds leading positions in the markets it serves across the globe. Our single-use products that have meanwhile become established in nearly all process steps are playing an increasingly important role in the manufacture of biopharmaceuticals. As a result, we help our customers produce biological medications and vaccines safely and efficiently.
Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development. A leader in centrifugation and flow cytometry, Beckman Coulter has long been an innovator in life sciences instruments and solutions used at the forefront of important areas of investigation, including genomics, proteomics and cellular research.
Werum IT Solutions is the world’s leading supplier of manufacturing execution systems (MES) and manufacturing IT solutions for the pharmaceutical and biopharmaceutical industries. Its PAS-X software product is run by the majority of the world’s top 30 pharmaceutical and biotech companies and also by many mid-sized manufacturers.
Werum is working side by side with many of the commercial pioneers in the fast growing cell and gene therapy sector focusing on managing the complex processes involved in the manufacturing and transport of these personalized medicines.
Werum’s manufacturing IT solutions help pharma manufacturers to increase efficiency, improve productivity, and meet regulatory requirements. Founded in 1969, Werum is headquartered in Lüneburg, Germany, and has many locations in Europe, America, and Asia.
Werum is part of Medipak Systems, the Pharma Systems business area of the international technology group Körber. The Körber group unites around 12,000 professionals in industry-leading companies worldwide, achieving annual earnings of 2.6 billion Euros.
MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs in a broad range of conditions. MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, and has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy and regenerative medicine space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world.
With 25 years of experience we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. As an ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.
CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products are used to help care for critically and chronically ill patients. The people of Fresenius Kabi are driven by a common purpose to put lifesaving medicines and technologies in the hands of people who care for patients, and to find answers to the challenges they face
Fresenius Kabi develops advanced transfusion medicine, cell therapy, infusion, and clinical nutrition technologies that help to increase the impact of donors and collectors in blood and plasma centers, scale the discoveries of researchers in biotechnology labs, and expand patient treatment options and enhance drug administration safety in acute care facilities.
Fresenius Kabi is dedicated to working with cell therapy labs of all sizes and stages to create cell processing systems to address the industry’s biggest research and manufacturing challenges, from process development to full commercialization.
HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.
Healthgen Biotechnology Corp. (Healthgen Biotech) is a private company founded in 2006. We are focusing on developing, manufacturing and marketing a series of environmental friendly and safe products by using the State-of-the-Art platform called OryzHiExp, having high capacity to express proteins or small peptides in the rice grain.
Using the OryzHiExp platform, Healthgen Biotech maximizes the innovative animal-free product development opportunities for clients and partners. Its cost-effective expression capability made it as a breakthrough expression platform.Healthgen Biotech has achievements in developing and commercializing products, such as OsrHSA, OsrbFGF, OsrIGF-1, OsrEGF, OsrLF, OsrAAT.
Healthgen Biotech’s Quality Control System has been certified by ISO 9001: 2008 and ensures standardized process as well as qualified products. Our scale production facility is compliant with GMP. All products can be used as the cell culture media supplements, industrial biological reagents in bio-pharmaceuticals processing and life science researches.
Obio is a leading high-tech enterprise in Shanghai, focusing on plasmid and virus one-stop services, from lab scale CRO, Investigator initiated trail (ITT), Gene therapy drug IND (CDMO) to GMP grade manufacturing (CMO). Company already established 10000m2 facility, including PD lab, QC lab, pilot plant, and GMP site. The technical team has more than 10 years biopharma industry experience, and has completed several gene therapy projects covering plasmid, AAV, Lentivirus, and different oncology viruses in past three years.
Since its inception, Alit has been providing advanced equipment, technology and services to the life sciences and biotechnology industries. We insist on improving product innovation and customer value to build a complete product supply system. In addition to the self-developed Countstar cell analyzer, we are also a partner of many European and American bio-equipment suppliers in China. Providing customers with all kinds of laboratory instruments, testing reagents and production equipment from R&D to manufacture. The company's customers are mainly China's leading biopharmaceutical, cell therapy, biomedical and various biotechnology companies, as well as a large number of life science basic research laboratory and government research institution. We have become an important supplier of instruments and equipment for the life sciences and biotechnology industries in China and have an excellent reputation in the industry.
The company was founded in 2005, with headquarters and R&D center in Shanghai, and offices in Europe, Beijing, Guangzhou and Chengdu. For more than ten years, I have adhered to our ideals and have not forgotten our original aspiration. With the faith of “innovation to change the future”, we adhere to global R&D and Chinese production. Until now, it has obtained a number of invention patents authorized by China, the United States and Japan. And we will continuously provide the most valuable products and technical solutions for the industrialization of life sciences.
Our motto is “Business is not our first purpose, but the most important thing is to improve ourselves and benefit others”. We believe that our team has the same value as our customers, which is bringing the happiness to the world. To face the future, all “Alit” people will continue to develop their professional skills by accumulated over the years of experience to provide customers with high quality service, high value innovative products and technical solutions.
Polyplus-transfection ® SA is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in France, Polyplus-transfection® applies it’s 17+ year expertise to the development of novel transfection solutions for mammalian cells. We provide reagents for high yield transient protein and antibody production in CHO and HEK-293 cells, as well as for viral vector production for Gene and Cell Therapy (PEIpro product range). Our products meet the quality requirements for use in bioprocesses up to GMP grade.
Charles River Laboratories, Inc. is a leading contract research service provider. We help accelerate drug development by supporting our clients’ research every step of the way. Microbial Solutions is one of the business segments of Charles River. We’ve purposely built our portfolio to bring you progressive products and services that deliver accurate, relevant, and reliable data to fuel confident decisions on product quality and contamination control. We lead the market with products and services that meet the diverse needs of the pharmaceutical, home, beauty, dairy, beverage, and food industries. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection, and Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost to manufacture, and protects your reputation.
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
AUSTAR Lifesciences Limited (the“Company”), together with its subsidiaries (collectively as the "Group") are a leading provider of integrated engineering solutions with high-end and comprehensive services and products to reputable pharmaceutical manufacturers and research institutes in the PRC and also a provider of the services and products to customers in emerging countries. On 7 November 2014 , the Company (Stock code: 6118) was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Group was founded in 1991 with its headquarter based at Beijing, PRC. We can assist our customers in key phases of pharmaceutical product lifecycle. We, together with our joint ventures, also engage in the manufacture, sale and distribution of various types of high-end pharmaceutical equipment and life science consumables, we offer a variety of quality products in our product portfolio to our customers.
Porton Pharma Solutions Ltd. (former name: Porton Fine Chemicals Ltd) founded in 2005, is a top-tier CDMO, providing services to the global pharmaceutical industry with intergraded research, development and manufacturing of custom drug intermediates and APIs.
We operate three Process R&D Centers, and three Manufacturing Sites across China, and leading US based CRO J-Star with expertise in GMP/GLP synthesis, Crystallization research and High potent handling etc.
Supported by >1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across China, North America and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and high-quality, cost-effective manufacture of APIs and/or drug intermediates.
Ask Us How We Can Help You @ www.porton.cn
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
GigaCeuticals Co., Ltd. is aiming at accelerating drug discovery by combining various technologies, including artificial intelligence, systems biology and big data. GigaCeuticals offers prediction, validation and design of small molecule drugs in a multiple purposes fashion against aging related diseases, metabolic diseases and other chronic diseases, which lack of explicit targets or involving a multiple targets mechanism. Currently, the experimentally validated model, at animal level, including extending longevity, anti-obesity, treating hyperuricemia and anti-oxidant / fibrosis.
There are several ways we offer services: i) we predict and validate clients’ self-owned drug-like library using validated model and return top-hit list with experimental reports. ii) We co-develop novel small molecules against certain disease with CRO companies. iii) We sell or license IPs. Other models are under validation including NAFLD/NASH, epilepsy, stem cell renewal, tendon healing, cancer, immunity boost, Alzheimer’s’ disease and etc.
The small molecules we developed has followed properties: i) comparable or better effect than known drugs (first / best-in-class), ii) multiple candidates with similar effects, iii) with multiple purposes, like treating hyperuricemia and anti-fibrosis, iv) with less ADRs. v) continually designing candidates until fulfill all needs, vi) go with novel targets / mechanisms identified.
JenKem Technology is dedicated to the development and supply of PEG-based products and custom PEGylation services, with worldwide distribution, and the recent significant addition of new R&D through commercial scale GMP facilities.
Development and manufacture of a wide range of PEG derivatives with high purity and low polydispersity, currently in 1 gram to 40 kg or greater sized batches, under ISO 9001 and ISO 13485 certified Quality Management Systems, following ICH Q7A guidelines and operating under cGMP protocols for regulated customers.
Custom synthesis of Y-Shaped PEGs, Methoxy PEGs, Homobifunctional PEGs, Heterobifunctional PEGs, Multi-arm PEGs, Multi-arm Heterobifunctional PEGs, Monodisperse (Discrete) PEGs, Biodegradable PEG Co-Polymers (such as PEG-PLGA, PEG-PLA, PEG-PCL, and other block polymers), and PEG GPC Standards.
Custom PEGylation of proteins, peptides, oligonucleotides, and small molecules; and conjugation of PEGs to other polymer systems. Large scale manufacturing on a custom synthesis basis, which offers the flexibility to match a customer’s specifications.
CAS, a division of the American Chemical Society, is dedicated to the ACS vision of improving people's lives through the transforming power of chemistry. The CAS team of highly trained scientists identifies, aggregates, and organizes all publicly disclosed chemistry information, creating the world's most valuable collection of content that is vital to innovation worldwide. Scientific researchers, patent professionals and business leaders around the world rely on a suite of research solutions from CAS that enables discovery and facilitates workflows to fuel tomorrow’s innovation. Flagship solutions include SciFinder®, SciFindern, and STNextTM.
E3 was founded by a group of veterans from the pharmaceutical industry determined to solve the serious problems with laboratory safety and energy-efficiency.
The advent of E3's patented breakthrough innovations, the Bernoulli Laminar Air-Curtain Containment Hood and SmartFlow Damper System, has brought forth a solution for the age-long global dilemma of having to compromise between laboratory safety and energy efficiency.
The Bernoulli Hood delivers exceptional "zero-spill" containment safety performance while simultaneous providing unparalleled energy efficiency of up to 80%. With the Bernoulli Hood, laboratory owners can enjoy an unprecedented level of worker safety and HVAC energy cost reduction, drastically reducing their laboratory carbon footprint to achieve an unforeseen level of sustainability.
The Bernoulli SmartFlow Damper System is the most compact and simplified airflow control solution in the world. With an accuracy of over 95% and a response time of less than 2.5 seconds, it is also the first and only product to control airflow through direct real-time measurement of flowrate. Its integrated and patented multi-vane technology eliminates the complexities and costs associated with airflow testing, adjusting and balancing work.
Shanghai Beshining Law Office was founded in 2013 by main partner Xue Qi and his team from Shanghai Zhixin Patent Agent Ltd., and its headquarters is located in Shanghai.
As one of the few leading law offices authorized to engage in patent and trademark, we currently house more than one hundred personnel including lawyers, patent attorneys, and other legal and technical professionals with diverse background and expertise.
Our partners and their team have been providing nearly thousands of domestic and foreign enterprises with full intellectual property legal service and comprehensive domestic and foreign legal service of patent, trademark, copyright, integrated circuit layout design, anti-unfair competition and trade secret. The quantities of patent applications, trademark applications and lawsuits are all top rated nationwide. Especially, our team in Chemistry, Pharmaceuticals and Biology in which we have 16 lawyers and 36 patent attorneys is in the top tier of China, and our firm enjoys a patent grant rate of over 90% for invention in such areas. For three consecutive years (2015-2017), our team was awarded the title of Outstanding IP Service Team in China by China IP Magazine and China Daily IPR Channel.
LexOrbis is one of the most recommended full service IP firms in India with offices at 3 locations namely, New Delhi, Mumbai and Bangalore. We have a strong team of over 65 attorneys including 46 patent attorneys having expertise in the field of mechanical, electronics, wireless communication, software, mobile applications, chemistry, biotechnology, etc. who are involved in drafting new patent applications originating from India and filing and prosecuting international patent applications. A team of over 19 lawyers at our firm also have deep expertise in handling trademark prosecution and contentious cases. Our patent and trademark attorneys work in combination with our IP litigators to handle a large number contentious IP cases such as pre-and post- grant oppositions, cancellation and infringement suits and criminal enforcement of India rights in India.
Founded in 2011, we provide small molecule process development and manufacturing services to the pharmaceutical industry.
We evaluate our clients needs and provide creative solutions to deliver valuable, enabling compounds from small quantities of unique compounds to support early and pre-clinical development, to large volumes of key intermediates for clinical studies and commercial supply. In addition to all the chemistries you would expect from a world class small molecule developer, we have specialized expertise in developing chiral compounds, unnatural amino acids, and sulphur containing molecules.
Raffles operates 40,000 sq. ft of modern, well-equipped facilities across two sites in Guangdong, and a business development and technical support function in Philadelphia.
Help Stem Cell Innovations is a leading clinical-stage biotechnology company in Nanjing, China, dedicating to the development of next-generation cell-based therapeutics for degenerative diseases. Our first-in-class cell therapy candidates undergoing clinical development utilize human induced pluripotent stem cells (iPSC) generated from our proprietary iPSC platform. By restoring function, these next-generation medicines have the potential to revolutionize current treatment paradigm.
Human iPSC also represents a powerful platform for drug discovery and efficacy evaluation. Assessment of drug safety and efficacy is complex and time consuming. We support our customers by providing high quality, standardized human iPSC-derived cardiomyocytes and neural cells specially designed for drug screening. Together with our customized high-throughput assays, our stem cell products effectively decrease drug attrition rate and costs in drug development processes.
Beijing HFK Bioscience Co. Ltd. (HFK) was founded in 2008 in conjunction with theInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, in Changping District, Beijing, China. HFK is dedicated to developing and providing laboratory animals, animal models for human diseases,laboratory animal diets and related services.HFK's success results from its large group of experienced researchers and innovative elite with its high emphasis on quality. The quality of its products and services is beijing maintained by this large and dedicated research group and consultant team comprised
by international and domestic experts in the field of laboratory animal science. HFK consists of four branches: the Laboratory Animal Resources (LAR), the Laboratory Animal Diets (LAD), the Research and Development (R&D) and Quality Assurance Unit(QAU).
◆The LAR provides more than 1,000,000 SPF rodents annually, including 200 strains of spontaneous and genetically engineered animal models for human diseases.
◆The LAD owns an automated manufacturing system with the capability to produce 5,000 tons of a wide array of high quality diets per year, including specialformulated diets for all kinds of laboratory animal. All diets are in compliance with GLP standards.
◆The R&D offers the service for generating animal models for human diseases,including the surgical, chemical or diet induced, transgenic, gene knock-in or gene knock-out animal models. Cryopreservation and cryorecovery services are alsoavailable.
◆The QAU is independent of other branches, with advanced equipments and a well trained team. The unit is responsible for running the ISO9001 quality management system of the company.
We look forward to working with you to provide you with your basic research needs. We are dedicated to provide you the utmost in quality and price.
China Medical City (Taizhou National Medical High-tech Zone) is located in Taizhou City, Jiangsu Province. As the first national level life science hi-tech Park, China Medical City (CMC) is jointly built by Ministry of Science and Technology, China Food and Drug Administration (CFDA), National Health and Family Planning Commission, China Administration of Traditional Chinese Medicine and Jiangsu Provincial Government. Jiangsu CFDA CMC Branch, Jiangsu Food and Drug Inspection Institute CMC Branch, Jiangsu Medical Device Testing Center CMC Branch have been established successively to better support the industry and offer services to the companies more efficiently.
We are committed to building the largest life scienceindustrial base with the most integrated industrial chainin China. China Medical City has cooperated with over 50 famous life science R&D institutes domestic and abroad, and there are over 900 companies including AstraZeneca, Boehringer Ingelheim, Nestle, Sanofi-Pasteur, and Takeda in China Medical City.
China Medical City, a new city for life science industryin China, your first choice for investment!